TWENTY-FOUR HOUR DIURNAL CURVE COMPARISON OF COMMERCIALLY AVAILABLE BIMATOPROST 0.03% VERSUS TIMOLOL MALEATE 0.5%/OORZOLAMIDE 2% FIXED COMBINATION

Purpose: To evaluate the efficacy and safety of bimatoprost 0.03 percent given every evening versus timolol maleate 0.5 per-cent/dorzolamide 2 percent fixed combination (TDFC) given twice daily in open-angle glaucoma and ocular hypertensive patients. Design: A single-masked, two center, crossover comparison with two eight-week treatment periods following a four-week medicine free run-in period. Diurnal curve intraoc-